Natco Pharma Ltd.

BSE: NATCOPHARM524816ISIN INE987B01026

Healthcare
Pharmaceuticals
BSE 500

BSE listing

Share price

₹813.90-4.85 (-0.59%)

as of 18 Sep 2026

52W high: ₹1,226.10
52W low: ₹789.30
Off 52W high: -33.62%
1M return: -8.25%
3M return: -8.42%
6M return: -15.03%
1Y return: -7.96%
20D avg volume: 41,738
50 DMA: ₹893.48
200 DMA: ₹944.43

Key ratios Consolidated

Market cap: ₹14,578 Cr
Current price: ₹813.90
52W high / low: ₹1,226.10 / ₹789.30
Face value: ₹2.00
P/E: 12.73
P/B: —
EPS (TTM): ₹63.91
Book value / share: —
ROE: —
ROCE: 16.30%
Operating margin: —
Net margin: —
Debt / equity: 0.08
Net debt: ₹507.50 Cr
Interest cover: 41.62
Dividend yield: 0.55%
Dividend / share (TTM): ₹4.50
Payout: 7.04%
Cash conversion cycle: 123.6 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	735.20	739.10	647.30	1,363	1,329	1,221	474.80	1,371	1,363	1,068	758.60	1,031
	59.20	77.80	58.10	100.00	61.70	66.30	176.30	63.80	48.10	42.00	37.00	29.40
	608.80	672.80	544.30	849.30	818.70	781.40	487.40	616.70	607.10	632.70	539.30	621.20
	157.80	102.80	135.20	174.90	180.60	169.00	72.70	143.20	151.30	127.60	92.20	166.50
	27.80	37.50	55.80	72.60	37.30	40.80	39.10	53.70	32.50	31.10	36.70	41.00
	179.30	158.50	159.40	200.30	169.00	159.40	141.60	151.50	142.00	142.50	121.90	122.40
	13.00	10.90	9.50	13.10	3.20	10.20	4.40	4.10	5.20	6.20	4.60	4.20
	47.10	50.40	46.20	52.40	57.60	98.30	47.00	45.80	44.10	55.50	44.20	43.60
	221.90	298.30	196.10	413.80	355.90	264.30	211.60	237.70	235.60	285.90	206.40	235.20
	185.60	144.10	161.10	613.70	571.90	505.90	163.70	818.20	803.60	477.60	256.30	439.60
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	185.60	144.10	161.10	613.70	571.90	505.90	163.70	818.20	803.60	477.60	256.30	439.60
	63.40	89.20	20.70	95.80	91.60	99.90	31.30	141.70	135.10	91.30	43.60	70.60
	206.50	269.00	151.30	517.90	480.30	406.00	132.40	676.50	668.50	386.30	212.70	369.00
	11.53	14.96	8.46	28.94	26.84	22.70	7.43	37.81	37.32	21.56	11.88	20.60
Key metrics
	245.70	205.40	216.80	679.20	632.70	614.40	215.10	868.10	852.90	539.30	305.10	487.40
	33.40%	27.80%	33.50%	49.80%	47.60%	50.30%	45.30%	63.30%	62.60%	50.50%	40.20%	47.30%
	28.10%	36.40%	23.40%	38.00%	36.10%	33.30%	27.90%	49.30%	49.10%	36.20%	28.00%	35.80%
	—	1.70%	—	7.20%	—	6.70%	—	—	—	—	—	—
	-44.70%	-39.50%	36.30%	-0.60%	-2.50%	14.30%	-37.40%	32.90%	—	—	—	—
	-57.00%	-33.70%	14.30%	-23.40%	-28.20%	5.10%	-37.80%	83.30%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	3,485	4,078	4,430	3,999	2,707	1,945	2,052	1,915	2,094	2,202	2,065
	295.10	297.60	354.50	128.10	104.60	99.00	103.60	107.40	130.20	40.40	13.90
	2,675	2,885	2,493	2,453	1,950	1,842	1,576	1,454	1,400	1,355	1,454
	570.70	593.50	536.20	522.50	475.30	519.20	372.90	329.00	333.10	390.50	520.80
	193.70	203.20	166.10	151.40	175.70	58.50	186.60	127.80	55.00	45.90	97.10
	697.50	687.20	594.50	525.00	486.70	444.80	414.90	375.00	355.90	325.60	243.20
	46.50	36.70	23.90	19.20	14.50	17.70	13.30	21.50	19.30	15.40	18.50
	196.10	206.60	235.20	186.80	163.80	142.60	116.90	99.80	81.00	—	54.40
	1,130	1,264	949.20	1,006	—	675.60	—	—	589.60	519.70	539.30
	1,104	1,491	2,291	1,674	861.90	202.20	579.60	568.70	824.70	887.20	624.40
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	1,104	1,491	2,291	1,674	861.90	202.20	579.60	568.70	824.70	887.20	624.40
	269.10	118.90	408.00	285.20	146.60	32.20	137.20	110.60	182.30	192.00	139.50
	1,145	1,418	1,883	1,388	715.30	170.00	442.40	458.10	642.40	695.20	484.90
	63.89	79.20	105.26	77.34	39.18	9.32	24.20	25.33	34.98	—	—
Key metrics
	1,347	1,734	2,550	1,880	1,040	362.50	709.80	690.00	925.00	902.60	697.30
	38.66%	42.50%	57.60%	47.00%	38.40%	18.60%	34.60%	36.00%	44.20%	41.00%	33.80%
	32.85%	34.80%	42.50%	34.70%	26.40%	8.70%	21.60%	23.90%	30.70%	31.60%	23.50%
	—	16.30%	30.10%	—	—	—	—	—	—	—	—
	—	-7.90%	10.80%	47.70%	39.20%	-5.20%	7.20%	-8.60%	-4.90%	6.60%	—
	—	-24.70%	35.70%	94.10%	320.80%	-61.60%	-3.40%	-28.70%	-7.60%	43.40%	—
	—	1,380	1,296	—	—	—	—	—	—	—	—
	—	1.25	0.90	—	—	—	—	—	—	—	—
	—	0.08	0.04	—	—	—	—	—	—	—	—
	—	507.50	153.10	—	—	—	—	—	—	—	—
	—	123.6	143.1	—	—	—	—	—	—	—	—
Balance sheet
	—	11,074	8,631	—	—	—	—	—	—	—	—
	—	5,052	5,270	—	—	—	—	—	—	—	—
	—	198.90	120.00	—	—	—	—	—	—	—	—
	—	881.20	1,247	—	—	—	—	—	—	—	—
	—	908.50	765.80	—	—	—	—	—	—	—	—
	—	381.90	330.90	—	—	—	—	—	—	—	—
	—	2,545	2,432	—	—	—	—	—	—	—	—
	—	409.30	274.90	—	—	—	—	—	—	—	—
	—	1,681	943.50	—	—	—	—	—	—	—	—
	—	706.40	273.10	—	—	—	—	—	—	—	—
	—	606.40	273.10	—	—	—	—	—	—	—	—
	—	100.00	0.00	—	—	—	—	—	—	—	—
	—	9,221	7,612	—	—	—	—	—	—	—	—
Cash flow
	—	1,768	1,697	—	—	—	—	—	—	—	—
	—	-2,143	-1,414	—	—	—	—	—	—	—	—
	—	297.50	-210.70	—	—	—	—	—	—	—	—
	—	388.30	401.10	—	—	—	—	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	596.60	608.80	528.80	1,264	1,193	1,157	407.60	1,293	1,237	964.80	625.30	930.50
	48.30	72.90	55.30	93.30	59.60	62.10	168.00	51.40	39.80	35.90	29.50	24.70
	542.90	571.70	458.90	771.60	709.40	698.70	425.30	547.10	518.70	568.20	431.20	531.20
	157.80	102.80	135.20	174.90	180.60	169.00	72.70	143.20	151.30	127.60	92.20	166.60
	0.40	13.30	7.60	20.60	7.90	9.70	14.80	13.30	7.70	8.00	11.10	6.80
	151.40	133.10	136.50	178.60	143.50	138.70	123.60	132.80	120.20	125.00	103.90	106.80
	9.60	9.70	8.30	11.70	2.60	8.80	3.40	3.00	4.40	4.50	3.80	3.00
	42.70	45.60	42.10	48.10	53.80	93.70	43.70	42.20	40.40	51.60	40.40	40.00
	182.50	259.50	160.30	378.70	325.80	235.90	184.30	213.30	208.10	281.20	172.40	200.50
	102.00	110.00	125.20	586.00	542.90	520.80	150.30	796.90	758.00	432.50	223.60	424.00
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	102.00	110.00	125.20	586.00	542.90	520.80	150.30	796.90	758.00	432.50	223.60	424.00
	27.40	-99.60	18.30	85.10	78.80	92.70	25.40	135.80	121.70	83.40	31.60	63.80
	74.60	209.60	106.90	500.90	464.10	428.10	124.90	661.10	636.30	349.10	192.00	360.20
	4.17	11.70	5.97	27.97	25.91	23.90	6.97	36.91	35.53	19.49	10.72	20.11
Key metrics
	154.30	165.30	175.60	645.80	599.30	623.30	197.40	842.10	802.80	488.60	267.80	467.00
	25.90%	27.20%	33.20%	51.10%	50.20%	53.90%	48.40%	65.10%	64.90%	50.60%	42.80%	50.20%
	12.50%	34.40%	20.20%	39.60%	38.90%	37.00%	30.60%	51.10%	51.40%	36.20%	30.70%	38.70%
	—	1.40%	—	7.20%	—	7.20%	—	—	—	—	—	—
	-50.00%	-47.40%	29.70%	-2.20%	-3.60%	20.00%	-34.80%	38.90%	—	—	—	—
	-83.90%	-51.00%	-14.40%	-24.20%	-27.10%	22.60%	-34.90%	83.50%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	2,998	3,595	4,094	3,569	2,351	1,768	1,654	1,790	1,986	2,108	2,003
	269.80	281.10	321.30	104.70	85.50	94.60	101.10	123.80	129.80	39.40	13.20
	2,345	2,512	2,190	2,118	1,666	1,706	1,362	1,331	1,269	1,260	1,382
	570.70	593.50	536.20	522.50	475.30	519.20	372.90	329.00	333.10	390.50	520.80
	41.90	49.40	45.50	34.80	19.80	20.90	174.00	123.90	31.50	22.70	68.70
	599.60	591.70	515.30	454.90	425.70	410.10	380.00	356.10	340.20	312.20	232.10
	39.30	32.30	19.60	14.50	8.60	13.30	11.30	20.60	18.80	14.70	17.50
	178.50	189.60	220.00	171.90	150.90	138.40	115.20	98.10	80.10	65.50	53.60
	981.00	1,124	841.60	902.50	—	—	—	—	490.50	462.20	505.90
	923.20	1,364	2,226	1,555	770.70	155.90	392.20	583.10	847.40	887.60	634.10
	0.00	0.00	0.00	—	—	—	—	—	—	—	—
	923.20	1,364	2,226	1,555	770.70	155.90	392.20	583.10	847.40	887.60	634.10
	31.20	82.60	375.60	248.70	133.60	16.80	82.70	108.60	180.30	189.40	139.30
	892.00	1,282	1,850	1,307	637.10	139.10	309.50	474.50	667.10	698.20	494.80
	49.81	71.55	103.31	72.79	34.90	7.63	16.99	26.08	36.22	—	—
Key metrics
	1,141	1,586	2,466	1,742	930.20	307.60	518.70	701.80	946.30	967.80	705.20
	38.05%	44.10%	60.20%	48.80%	39.60%	17.40%	31.40%	39.20%	47.60%	45.90%	35.20%
	29.75%	35.70%	45.20%	36.60%	27.10%	7.90%	18.70%	26.50%	33.60%	33.10%	24.70%
	—	16.00%	30.30%	—	—	—	—	—	—	—	—
	—	-12.20%	14.70%	51.80%	33.00%	6.90%	-7.60%	-9.90%	-5.80%	5.30%	—
	—	-30.70%	41.60%	105.10%	358.00%	-55.10%	-34.80%	-28.90%	-4.50%	41.10%	—
	—	1,393	1,258	—	—	—	—	—	—	—	—
	—	1.39	0.90	—	—	—	—	—	—	—	—
	—	0.08	0.04	—	—	—	—	—	—	—	—
	—	694.90	261.90	—	—	—	—	—	—	—	—
	—	113.5	142.1	—	—	—	—	—	—	—	—
Balance sheet
	—	10,287	8,270	—	—	—	—	—	—	—	—
	—	4,320	4,688	—	—	—	—	—	—	—	—
	—	11.50	11.20	—	—	—	—	—	—	—	—
	—	759.60	1,178	—	—	—	—	—	—	—	—
	—	723.60	642.10	—	—	—	—	—	—	—	—
	—	332.00	298.40	—	—	—	—	—	—	—	—
	—	2,520	2,410	—	—	—	—	—	—	—	—
	—	365.30	225.10	—	—	—	—	—	—	—	—
	—	1,566	864.60	—	—	—	—	—	—	—	—
	—	706.40	273.10	—	—	—	—	—	—	—	—
	—	606.40	273.10	—	—	—	—	—	—	—	—
	—	100.00	0.00	—	—	—	—	—	—	—	—
	—	8,553	7,334	—	—	—	—	—	—	—	—
Cash flow
	—	1,776	1,662	—	—	—	—	—	—	—	—
	—	-2,078	-1,444	—	—	—	—	—	—	—	—
	—	302.10	-212.40	—	—	—	—	—	—	—	—
	—	383.30	403.70	—	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +15.20%
Sales CAGR 5Y: +16.80%
Sales CAGR 10Y: —
Profit CAGR 3Y: +26.23%
Profit CAGR 5Y: +32.87%
Profit CAGR 10Y: —
Sales YoY (TTM): -25.97%
Profit YoY (TTM): -46.85%

Consolidated

Sales CAGR 3Y: +14.64%
Sales CAGR 5Y: +14.72%
Sales CAGR 10Y: —
Profit CAGR 3Y: +25.64%
Profit CAGR 5Y: +26.24%
Profit CAGR 10Y: —
Sales YoY (TTM): -20.73%
Profit YoY (TTM): -32.47%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Filings & corporate actions

Recent announcements

Draft letter of Offer9 Sep 2026 · Company Update / Issue of Securities
Outcome of Board Meeting9 Sep 2026 · Board Meeting / Outcome of Board Meeting
News Paper Publication5 Sep 2026 · Company Update / Newspaper Publication
Notice of 43rd Annual General Meeting of the Company scheduled to be held on Wednesday, the September 30, 2026 at 11:00 AM (IST)4 Sep 2026 · AGM/EGM / AGM
Business Responsibility and Sustainability Report4 Sep 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Annual Report for the FY 2025-264 Sep 2026 · Others / Reg. 34 (1) Annual Report
Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/09/2026 ,inter alia, to consider and approve Fund Raising4 Sep 2026 · Board Meeting / Board Meeting
Investor Meet2 Sep 2026 · Company Update / Analyst / Investor Meet
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Durga Devi Nannapaneni26 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Press Release & Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 regarding the investment in eGenesis, Inc.25 Aug 2026 · Company Update / Press Release / Media Release
Intimation of Investor Meet24 Aug 2026 · Company Update / Analyst / Investor Meet
Conclusion of US FDS Inspection at our Visakhapatnam, Andhra Pradesh, Finished Dosage (FDF) Unit21 Aug 2026 · Company Update / Press Release / Media Release
Investor Meet19 Aug 2026 · Company Update / Analyst / Investor Meet
Investor Presentation19 Aug 2026 · Company Update / Investor Presentation
Q1FY2026-27 Transcript for the Earnings call held on 14th August, 202618 Aug 2026 · Company Update / Earnings Call Transcript
Intimation of Investors meeting organised by Nuvama Wealth Management Limited and ICICI Securities Limited16 Aug 2026 · Company Update / Analyst / Investor Meet
Newspaper Publication for the Un-Audited Financial Results for the quarter ended June 30, 2026 and declaration of Interim Dividend for the FY ending 2026-27.16 Aug 2026 · Company Update / Newspaper Publication
Weblink of Audio Transcript for the earnings call held on 14th August, 2026 for Q1FY2026-2714 Aug 2026 · Company Update / Analyst / Investor Meet
Investor Presentation for the Q1FY2714 Aug 2026 · Company Update / Investor Presentation
Board of Directors at their Meeting held on today i.e. 14th August, 2026 had declared Interim Dividend of Rs.1.50 (75%) for face value of Rs.2/- each14 Aug 2026 · Corp. Action / Dividend
Outcome of Board Meeting14 Aug 2026 · Board Meeting / Outcome of Board Meeting
The Company will host an Earnings Call with Investors / Analysts on Friday, the 14th August, 2026 at 17:30 PM IST to discuss the Un-audited Financial Results of the Company for the quarter ....11 Aug 2026 · Company Update / Analyst / Investor Meet
Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Further to our earlier intimation ....11 Aug 2026 · Board Meeting / Board Meeting
Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Un-audited Financial Results for ....6 Aug 2026 · Board Meeting / Board Meeting
Press Release: NATCO receives Tentative Approval for Olaparib Tablets from the United States Food and Drug Administration (U.S. FDA)18 Jul 2026 · Company Update / Press Release / Media Release
Natco Pharma Limited completes acquisition of additional 13.25% stake in Adcock Ingram holdings Proprietary Limited14 Jul 2026 · Company Update / Press Release / Media Release
Order passed by Assistant Commissioner (ST)(FAC), Tenali Circle, Tenali, Andhra Pradesh14 Jul 2026 · Company Update / Award of Order / Receipt of Order
Compliance Certificate under Reg.74(5) of SEBI (DP) Regulations, 20189 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Outcome of Board Meeting8 Jul 2026 · Others / Outcome without intimation
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 20156 Jul 2026 · Company Update / Change in Management
Superannuation of Mr. N. Malleswara Rao, Vice President - Operations, Pharma Division, Kothur w.e.f. closure of business hours on 30th June, 202630 Jun 2026 · Company Update / Change in Management
Closure of Trading Window30 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Earning call Transcript for the concall held on May 29, 20264 Jun 2026 · Company Update / Earnings Call Transcript
NATCO Pharma Limited and Lupin Limited receive approval from U.S. FDA for Eribulin Mesylate Injection3 Jun 2026 · Company Update / Press Release / Media Release
Newspaper Publication of Annual Audited Financial Results for the Quarter and Year ended March 31, 202630 May 2026 · Company Update / Newspaper Publication
Audio Link of Concall held on May 29, 202630 May 2026 · Company Update / Analyst / Investor Meet
FY26 Earnings Call Investor Presentation29 May 2026 · Company Update / Investor Presentation
Audited Financial Results for the quarter and year ended 31st March, 202629 May 2026 · Result / Financial Results
Audited Financial Results for the quarter and year ended 31st March, 202629 May 2026 · Board Meeting / Outcome of Board Meeting
Annual Secretarial Compliance Report for FY 2025-2626 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance

Corporate actions

Purpose	Ex date	Record date	Payment date
Interim Dividend - Rs. - 1.5000	20 Aug 2026	20 Aug 2026	—
Interim Dividend - Rs. - 1.5000	18 Feb 2026	18 Feb 2026	—
Interim Dividend - Rs. - 1.5000	20 Nov 2025	20 Nov 2025	—
Interim Dividend - Rs. - 2.0000	19 Aug 2025	19 Aug 2025	—
Interim Dividend - Rs. - 1.5000	18 Feb 2025	18 Feb 2025	—
Interim Dividend - Rs. - 1.5000	27 Nov 2024	27 Nov 2024	—
Interim Dividend - Rs. - 3.0000	23 Aug 2024	23 Aug 2024	—

Board meetings

14 Aug 2026 Board Meeting - Financial Results